Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 20 April 2026Expected publication date: TBC